Company intelligence / Profile preview
Evofem Biosciences, Inc.
- Ownership
- Public · EVFM
- Employees
- ~75
- Development stage
- Commercial
Overview
Evofem Biosciences has commercialized Phexxi®, an FDA-approved hormone-free contraceptive vaginal gel. The company also markets SOLOSEC®, an FDA-approved single-dose oral antibiotic for the treatment of bacterial vaginosis and trichomoniasis. Pipeline programs include EVO100 for STI prevention in Phase 3 trials and EVO200 for recurrent BV in early clinical stages. A multipurpose product candidate targeting HIV prevention via a partnership with Orion Biotechnology remains preclinical[5][6][7][9].
- Therapeutic areas
- Infectious DiseasesWomen's Health
- Modalities
- vaginal pH modulators (non-hormonal)oral antibiotics
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Evofem Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evofem Biosciences, Inc..